Chord Therapeutics was launched by Omega Funds in October 2020 to develop new oral treatments for rare neuroinflammatory diseases Merck to accelerate development of Chord’s innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD) ‍Focused expansion in neuroinflammatory diseases builds on Merck’s existing neurology portfolio in Multiple Sclerosis (MS)  Geneva, December […]